Palbociclib

Palbociclib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Solid Tumor、HR+/HER2- Breast Cancer、HR+, HER2-, Advanced Breast Cancer、CCNE1 Amplification。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Palbociclib 研究

• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

  不适用招募中美国NCT06388122

• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  III 期招募中美国Argentina澳大利亚比利时NCT06757634

• Immunomonitoring of Breast Cancer Patients During Systemic Treatment

  不适用招募中法国NCT04925856

• A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

  I 期 / II 期招募中中国NCT05953350

• SNV4818 in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国澳大利亚加拿大NCT06736704

• Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

  I 期 / II 期招募中美国NCT07558733

• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

  II 期招募中中国NCT07180160

• Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

  II 期招募中德国NCT06207734

• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

  不适用招募中中国NCT06856200

• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国比利时法国德国NCT05768139

• Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

  I 期 / II 期招募中中国NCT06895733

• Analysis of Circulating Tumor Markers in Blood

  不适用招募中法国NCT04025541

• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

  II 期招募中加拿大NCT03297606

• Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

  不适用招募中中国NCT06478927

• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

  II 期招募中奥地利比利时法国德国NCT06486883

• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

  II 期招募中美国NCT06062498

• Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  III 期招募中美国Argentina澳大利亚奥地利NCT06380751

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  III 期招募中美国Argentina澳大利亚比利时NCT07174336

• To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

  不适用招募中意大利NCT04660435

• T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

  III 期招募中美国NCT07683754

• Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

  不适用招募中意大利NCT07021911

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  II 期招募中美国Puerto RicoNCT05564377

• A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  I 期招募中美国西班牙NCT05683418

• Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

  I 期 / II 期招募中中国NCT06364956

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。